Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation

Early Phase 1 Completed NCT04130061

Summary

This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.

Number of Participants With Adverse Events

1 month · Participants

Number of Participants With Post Op Atrial Fibrillation Between Patients Who Receive hAM and Controls

1 month · Participants

proBNP (Serum) Between Groups at Time of Surgery

Surgery · pg/mL

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
• Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
• Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation — Massachusetts General Hospital
• Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.

All trials